Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in the JMP Securities Hematology and Oncology Summit
November 29, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
November 19, 2021 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
November 10, 2021 16:10 ET | Vor Biopharma
VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML ...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
November 09, 2021 08:30 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Two Upcoming Investor Conferences
November 08, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Present New Platform and Preclinical Data at ASH
November 04, 2021 09:15 ET | Vor Biopharma
Knock out of CD123 or CLL-1 by CRISPR-Cas9 from Human Hematopoietic Stem Cells Maintains Hematopoietic Function and is Resistant to Targeted TherapiesMultiplex Engineering of Human CD34+ HSPCs Enables...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
October 19, 2021 07:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
October 12, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as...
Vor-Wordmark-RGB-FullColor-070920.png
VOR33 Granted U.S. FDA Fast Track Designation for AML
September 09, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Three Upcoming Investor Conferences
September 02, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in...